title: T1hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?
abstract: There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to date in cadaveric human studies, clinical studies of patients and from animal models. Evidence for the potential route of entry into the brain will be examined. The current state of knowledge of effects of Gd accumulation in the brain is discussed. We will then discuss what the possible implications may be for the choice of Gd-based contrast agents in clinical practice.
authors.affiliation: 1 Academic Unit of Radiology, INSIGNEO, University of Sheffield, Sheffield, UK.
authors.forename: Nigel
authors.initials: N
authors.lastname: Hoggard
authors.affiliation: 2 Glasgow Royal Infirmary, University of Glasgow, Glasgow, UK.
authors.forename: Giles H
authors.initials: GH
authors.lastname: Roditi
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects*; D003287:Contrast Media / Q000493:pharmacokinetics*; D019786:Gadolinium DTPA / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000009:adverse effects / Q000379:methods*; D059906:Neuroimaging / Q000009:adverse effects / Q000379:methods; D061214:Patient Safety; D018570:Risk Assessment
chemical_list: D003287:Contrast Media; D019786:Gadolinium DTPA